PUBLICATION IN ACCORDANCE WITH ARTICLE 15 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
(Thomson Reuters ONE) -
REGULATED INFORMATION
GHENT, Belgium, 18 March 2010 - Ablynx [Euronext Brussels: ABLX], the
biopharmaceutical company focused on the discovery and development of
Nanobodies(®), announces that closing of its Secondary Public Offering (the
"SPO" or "Offering") has occurred today, 18 March 2010, as a result of which
6,666,667 new shares have been issued by Ablynx NV.
Ablynx NV also publishes the following information in accordance with Article
15 of the Belgian Law of 2 May 2007 regarding the publication of major
shareholdings in issuers whose securities are admitted to trading on a regulated
market (the "Transparency Law"):
Total amount of the capital of the Company:
?81,464,527.71
Total number of voting
securities: 43,590,173
Total number of voting rights (denominator): 43,590,173
Ablynx NV has an aggregate of 3,605,770 outstanding warrants, 2,538,822 warrants
of which entitle their holders to an aggregate of 1,269,411 shares (two warrants
giving right to subscribe for one share) and 1,066,947 warrants of which entitle
their holders to an aggregate of 1,066,947 shares (one warrant giving right to
subscribe for one share). The aggregate number of voting rights that can be
obtained upon exercise of the outstanding warrants amounts to 2,336,358.
Ablynx NV has not issued any other rights to subscribe for voting securities
that have not yet been issued or any shares without voting rights.
The voting securities of Ablynx NV are not divided into categories.
The Articles of Association of Ablynx NV provide for an additional notification
threshold of 3%.
This information is valid as of 18 March 2010. In accordance with the
Transparency Law, changes to the information set out above will be published
ultimately by the end of the calendar month during which the relevant change has
occurred.
-ends-
For more information, please contact Ablynx:
Dr. Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com
Eva-Lotta Allan
Chief Business Officer
t: +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
e: eva-lotta.allan(at)ablynx.com
Wim Ottevaere
Chief Financial Officer
t: +32 (0)9 262 00 08
e: wim.ottevaere(at)ablynx.com
[HUG#1395430]
Complete version of the press release: http://hugin.info/137912/R/1395430/352222.pdf
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 18.03.2010 - 13:01 Uhr
Sprache: Deutsch
News-ID 1011602
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Ghent
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 183 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"PUBLICATION IN ACCORDANCE WITH ARTICLE 15 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
